FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

Educators and caregiversHealthcare ProfessionalMedication Safety
Written by Denise Kolakowski

Consider risks and benefits of continued use versus other treatments

Learn more from the FDA
Denise Kolakowski
Previous

Do Not Use E25Bio COVID-19 Tests: FDA Safety Communication
Next

Philips Respironics Recalls Certain Trilogy EVO Ventilators for Potential Health Risks from PE-PUR Foam